In this monocentric, retrospective observational cohort study, the incidence of ICU-acquired bacterial BSI was not different between immunocompromised and non-immunocompromised patients.

This suggests that the clinical management of ICU-acquired bacterial BSI should not differ between immunocompromised and non-immunocompromised patients.

Further studies are required to better assess the relationship between immunosuppression—both present at ICU admission or acquired during ICU stay—and the incidence, microbiology and outcomes of ICU-acquired infections in general, and ICU-acquired BSI specifically.

A total of 1,313 patients (66.9% males, median age 62 years) were included. Among them, 271 (20.6%) were immunocompromised at ICU admission. Severity scores at admission, the use of invasive devices and antibiotic exposure during ICU stay were comparable between groups.

Both prior to and after adjustment for pre‐specified baseline confounders, the 28-day cumulative incidence of ICU-acquired bacterial BSI was not statistically different between immunocompromised and non-immunocompromised patients.

Read More